All News
Filter News
Found 2,357 articles
-
Sensei Biotherapeutics Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/10/2022
Sensei Biotherapeutics, Inc. today presented preclinical data for SNS-101, a conditionally active VISTA-blocking antibody, as well as characterization of VSIG4, an immune checkpoint targeted by Sensei’s discovery-stage SNS-102 program, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.
-
Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)
11/10/2022
Cellectis published a manuscript in Frontiers Bioengineering and Biotechnology demonstrating the feasibility of efficient multiplex gene engineering using a combination of two different molecular tools: Cellectis’ TALEN® gene editing technology and a TALE-BE.
-
Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting
11/10/2022
Imugene Limited (ASX:IMU) are pleased to announce that data from preclinical studies of Imugene’s onCARlytics (CF33-CD19) oncolytic virus in combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells was presented at the renowned Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
-
Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results
11/9/2022
Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today reported recent business progress and third quarter 2022 financial results.
-
TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma
11/9/2022
TransCode Therapeutics, Inc. today reported positive preclinical results with its immunotherapy candidate, TTX-siPDL1, in pancreatic adenocarcinoma. After two weekly treatments with TTX-siPDL1 combined with the standard-of-care chemotherapeutic, gemcitabine, tumor volumes were 25% of those in untreated animals.
-
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
11/9/2022
Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, reported financial results for the third quarter ended September 30, 2022.
-
Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
11/9/2022
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2022.
-
Telesis Bio Inc. Reports Third Quarter 2022 Financial Results
11/8/2022
Telesis Bio Inc., a company enabling customers to accelerate the reading and writing of biology, reported financial results and business highlights for the third quarter ended September 30, 2022.
-
Verve Therapeutics’ base editing program has been forced into a detour after the FDA placed a hold on its investigational new drug application. Beam has also posted its own regulatory update.
-
The only patient in an FDA-sanctioned clinical trial assessing a CRISPR-based therapy for a rare form of Duchenne muscular dystrophy has died, according to study sponsor Cure Rare Disease.
-
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
11/7/2022
Repare Therapeutics Inc. today announced that members of its senior management team will participate at two investor conferences in November.
-
TransCode Therapeutics to Present at Sidoti Virtual Investor Conference
11/7/2022
TransCode Therapeutics, Inc. today announced that it will be presenting at the Sidoti Virtual Conference.
-
Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting
11/7/2022
Nkarta, Inc. (Nasdaq: NKTX) today announced the presentation of two preclinical data abstracts focused on its natural killer cell pipeline and proprietary manufacturing technology at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting and Pre-Conference Programs.
-
Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the AHA Scientific Sessions 2022
11/5/2022
Intellia Therapeutics, Inc. presented additional interim results from an ongoing Phase 1 clinical trial of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy in development as a single-dose treatment for transthyretin amyloidosis in collaboration with Regeneron Pharmaceuticals.
-
Cimeio Therapeutics Announces Acceptance of ASH Abstracts Detailing Pipeline
11/4/2022
Cimeio Therapeutics announced the acceptance of two abstracts for the company’s pipeline programs to be presented at the American Society of Hematology meeting in December 2022 in New Orleans.
-
Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
11/3/2022
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the third quarter ended September 30, 2022.
-
Regeneron Reports Third Quarter 2022 Financial and Operating Results
11/3/2022
Regeneron Pharmaceuticals, Inc. announced financial results for the third quarter of 2022 and provided a business update.
-
EdiGene to Present Preliminary Safety and Efficacy Results of an Investigator Initiated Trial for ET-01, its Investigational Gene Editing Hematopoietic Stem Cell Therapy, at the 64th ASH Annual Meeting and Exposition
11/3/2022
EdiGene, Inc. announced it will present preliminary safety and efficacy results for ET-01, its investigational gene-editing therapy for transfusion dependent β-thalassemia at the 64th American Society of Hematology Annual Meeting and Exposition on December 10-13, 2022 in New Orleans, Louisiana.
-
CRISPR Therapeutics Announces Poster Presentation on CTX110® at the American Society of Hematology (ASH) 2022 Annual Meeting
11/3/2022
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a poster on CTX110®, its wholly-owned allogeneic CAR-T cell investigational therapy targeting CD19+ B-cell malignancies, at the American Society of Hematology (ASH) 2022 Annual Meeting, taking place December 10-13, 2022.
-
The future of Editas Medicine’s EDIT-101 will be determined later in November after a data readout is available. The data could inform the company whether there is a potential commercial path forward.